Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report)'s stock price reached a new 52-week high on Thursday . The company traded as high as $17.41 and last traded at $16.99, with a volume of 111812 shares changing hands. The stock had previously closed at $16.26.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on the company. Guggenheim reiterated a "buy" rating and set a $19.00 target price on shares of Maze Therapeutics in a research report on Wednesday, April 2nd. Wedbush assumed coverage on Maze Therapeutics in a research report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 target price for the company. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Maze Therapeutics has a consensus rating of "Buy" and an average target price of $23.50.
Read Our Latest Report on MAZE
Maze Therapeutics Price Performance
The firm has a 50-day simple moving average of $12.33.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).
Institutional Trading of Maze Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the business. TRV GP IV LLC purchased a new position in shares of Maze Therapeutics in the first quarter valued at $66,874,000. Frazier Life Sciences Management L.P. purchased a new position in shares of Maze Therapeutics in the first quarter valued at $45,460,000. ARCH Venture Management LLC purchased a new position in shares of Maze Therapeutics in the first quarter valued at $45,362,000. Matrix Capital Management Company LP purchased a new position in shares of Maze Therapeutics in the first quarter valued at $27,373,000. Finally, Alphabet Inc. purchased a new position in shares of Maze Therapeutics in the first quarter valued at $26,561,000.
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Read More
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
